Best Genomics Companies in Canada
The 219 best Genomics companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Repare Therapeutics.
Canada's genomics sector has 219 tracked companies and $1.1B in disclosed funding, and if you want to know where the capital is actually concentrating, this page ranks the strongest Genomics companies in Canada by equity raised and recent funding momentum.
The headline number is $1.1B across 219 firms, but the distribution is steep. enGene leads at $54M, Feldan follows at $40M, and the rest cluster well below that. No unicorns yet. Investors like BDC, MaRS Discovery District and Fonds de solidarite FTQ are the repeat names backing this ecosystem, which tells you the funding is still largely institutional and domestic. The global backdrop is accelerating fast, though: the [genomics market was valued around $24.3B in 2021 and is forecast to reach $85.1B by 2030](https://countyenews.com/genomics-market-size-to-grow-by-usd-18244-34-million-from-2022-to-2027-north-america-is-estimated-to-contribute-37-to-the-global-market-growth/) at a 16.37% CAGR, driven by falling sequencing costs and rising demand for personalized medicine. And with Mukesh Ambani calling genomics a pillar of India's next decade, I'd say global conviction in this space is no longer a niche bet. Hot themes here, pharmacogenomics, machine learning drug discovery, nanomedicine, suggest Canada's next funding breakout could close that gap fast.
- Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 202
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Repare Therapeutics Developer of targeted therapies to address the genetic alterations associated with selected tumors | $166M | 72 mo ago | 180 | Daniel Durocher Co-Founder | — | — | 161 patents Small‑molecule kinase inhibitors for cancer therapy, focusing on PLK4, ATR, MYT1 targets. | — |
| 2 | Genizon BioSciences Genes and biomarkers discovery | $130M | 221 mo ago | — | Jan Mellegers Interim President & CEO | — | — | — | — |
| 3 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 77 mo ago | — | Xiaonan Wang Co-Founder & CTO | — | — | — | — |
| 4 | Angle Developer of cancer cell capture and analysis equipment | $81M | 47 mo ago | 176 | — | WordPressMySQLPHP+23 | Top 10M | — | — |
| 5 | ProNAi Therapeutics Developer of DNA-based gene therapies for cancer and other genetic diseases | $77M | 145 mo ago | — | Nick Glover President and CEO | — | — | — | — |
| 6 | Xagenic Provider of point-of-care molecular diagnostics for infectious diseases | $59M | 131 mo ago | 45 | — | — | — | 50 patents Electrochemical biosensor platforms and precision current‑mode DACs for point‑of‑care diagnostics | — |
| 7 | StageZero Life Sciences Developer of liquid biopsy test for the detection of cancer and multiple diseases | $59M | 46 mo ago | 40 | James Tripp CEO | Cart FunctionalityWeeblyMySQL+23 | Top 10M | — | — |
| 8 | enGene Developer of oral non-viral gene therapy platform 50Patents top 28%Moat top 29%Funding top 30%Innovation top 38% All 9 signals ▾Patentstop 28% Moattop 29% Fundingtop 30% Innovationtop 38% Newstop 46% Growthtop 48% Marketbottom 46% Techbottom 45% Globalbottom 44% Patents: 174 patents matched (strict assignee match) · 40 filings since 2022 vs 69 in 2017-21 Moat: Editorial + unicorn rating 6/10 · IP moat: 174 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $54M | 19 mo ago | 57 | — | WordPressApple iCloud MailMySQL+28 | Top 10M | 174 patents Chitosan nanoparticle gene delivery platforms for cancer immunotherapy and localized gene expression | 1 internship · 1 award |
| 9 | Feldan Developing delivery system of proteins inside cells directly 29Funding top 33%Moat top 38%Tech bottom 46%Market bottom 38% All 5 signals ▾Fundingtop 33% Moattop 38% Techbottom 46% Marketbottom 38% Globalbottom 37% Funding: Raised $40.4M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $40M | 14 mo ago | 36 | — | HubSpot CMS HubSplideIsotope+17 | Top 50M | — | — |
| 10 | Qvella Developer of a platform aimed to provide a more accurate and faster diagnosis of bacteria identification | $40M | 102 mo ago | 101 | — | — | — | 85 patents Rapid microbial diagnostics: cell separation, microcolony classification, and antibiotic susceptibility testing. | — |
| 11 | iVexSol Developer of a platform for the production of vectors | $39M | 40 mo ago | 34 | Rodney Rietze Co-Founder & CEO | — | — | — | — |
| 12 | Affinor Growers Developer of vertical farming technology and supplier of turnkey facilities | $38M | 44 mo ago | — | Nick Brusatore Founder & CEO | — | — | 17 patents Automated vertical farming towers for high‑density horticulture and controlled‑environment agriculture | — |
| 13 | Performance Plants Developer of technologies improving crop yields through stress tolerance and efficiency | $36M | 207 mo ago | 14 | Yafan Huang Chief Executive Officer | — | — | 106 patents Genetically engineered crops with enhanced water-use efficiency and stress tolerance. | — |
| 14 | PreciThera Developer of precision medicine for rare genetic bone diseases | $29M | 106 mo ago | 4 | — | — | — | 8 patents Therapeutic TGF‑β antagonist conjugates and fusion proteins for signaling inhibition | — |
| 15 | Fio Point-of-care digital diagnostic integrated with cloud information services for infectious diseases | $11M | 114 mo ago | 40 | Michael Greenberg Chairman and Chief Executive Officer | Cart FunctionalitySquarespace CommerceSquarespace+23 | Top 10M | 190 patents Point‑of‑care rapid immunoassay diagnostics with biomarker analytics and cloud data integration | — |
| 16 | Arbutus Bio Developer of nucleic acid-based therapeutics | $10M | 54 mo ago | 2 | — | DrupalPHPAmazon Web Services+20 | Top 10M | — | — |
| 17 | DelMar Pharmaceuticals Developer of drug candidates targeting orphan cancer indications | $8M | 70 mo ago | 3 | — | — | — | 24 patents Dianhydrogalactitol-based treatments for CNS and lung cancers, including combos and radiation | — |
| 18 | DxNA Developer and manufacturer of high value molecular diagnostic instruments | $7M | 126 mo ago | 15 | — | — | — | — | — |
| 19 | Prairie Plant Provider of technology to produce berry and other fruit plants for orchards | $6M | 118 mo ago | — | Brent Zettl Founder & CEO | — | — | 16 patents Plant genetic engineering for producing pharmaceutical proteins, cannabinoids, and plant extracts. | — |
| 20 | Sequence Bio Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases… | $5M | 82 mo ago | 20 | Chris Gardner CEO & President | DatoCMSApple iCloud MailGoogle Workspace+16 | Top 50M | — | — |
| 21 | Biomark Diagnostics Provider of metabolomics-based diagnostics for cancer | $5M | 14 mo ago | 6 | — | WordPressMySQLPHP+21 | Top 50M | — | — |
| 22 | Molecular You Developer of personalized multi-omic digital health platform 53Talent top 28%Innovation top 31%Patents top 31%Moat top 32% All 9 signals ▾Talenttop 28% Innovationtop 31% Patentstop 31% Moattop 32% Techtop 37% Fundingtop 47% Productbottom 48% Globalbottom 36% Marketbottom 33% Talent: Analyst team rating 4/5 Innovation: 24 patents (top 39% of patent-holders) · 19 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $5M | 10 mo ago | 28 | — | WordPressApple iCloud MailGoogle Workspace+28 | Top 10M | 24 patents Molecular diagnostics and personalized therapeutics for pancreatic cancer, Alzheimer's, autism. | 1 partnership |
| 23 | Avitia Provider of AI-powered diagnostics platform for molecular cancer testing solutions | $5M | 15 mo ago | — | James Lumsdaine Chief Executive Officer | WebflowGSAPAmazon Web Services+17 | Top 50M | — | — |
| 24 | Renaissance BioScience Developer of bioengineering technology for agriculture, food, health, and industrial markets | $5M | 28 mo ago | 22 | John Husnik Co-Founder & CEO | NginxGSAPjQuery+12 | Top 50M | 30 patents Engineered yeast for RNA delivery and asparagine reduction to lower acrylamide in foods | 1 job opening |
| 25 | Rapid Novor Provider of antibody sequencing & discovery services | $5M | 70 mo ago | 70 | — | WordPressMySQLPHP+17 | Top 5M | 23 patents Antibody sequencing, chain pairing, and immunoglobulin light‑chain dimer detection/quantification | 1 launch |
| 26 | GenXys Provider of pharmacogenetic testing and a medication decision support system | $4M | 63 mo ago | 17 | Martin Dawes Founder & CEO | WordPressMySQLPHP+34 | Top 50M | — | — |
| 27 | DoseBiome Provider of prebiotic and probiotic products | $4M | — | 9 | Ted Jin Founder & CEO | — | — | — | — |
| 28 | Prognomix Offers a diagnostic and predictive technology targeting Type 2 diabetes patients | $4M | 230 mo ago | — | Normand Balthazard ex-CEO | — | — | — | — |
| 29 | Med BioGene Provider of genomics-based test for the detection of early-stage lung cancer | $3M | — | 7 | — | — | — | — | — |
| 30 | Remedium AI Provider of an AI-based platform for drug discovery | $3M | — | — | Robert Murgita Founder | — | — | — | — |
| 31 | Nimble Science Developer of personalised medicine for gut health | $3M | 38 mo ago | 10 | Sabina Bruehlmann Co-Founder & CEO | Wix eCommerceWixSentry+13 | Top 50M | 16 patents Ingestible gastrointestinal sampling and targeted drug delivery devices and analysis systems | 1 partnership · 2 awards |
| 32 | Incisive Genetics Developer of gene editing delivery platform | $2M | 59 mo ago | 11 | Blair Leavitt Co-Founder & CEO | — | — | 20 patents CRISPR guide‑RNA designs for allele‑specific therapeutic gene editing of genetic diseases | — |
| 33 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 1 mo ago | — | John Bell Co-Founder | — | — | — | — |
| 34 | Mitomics Molecular diagnostics based on mitochnodrial genome | $2M | 152 mo ago | — | Christopher Mitton CEO | — | — | 57 patents Mitochondrial DNA deletion/ fusion biomarkers for cancer and UV‑damage diagnostics | — |
| 35 | Athletigen Sports genetics company - Analyses user's DNA | $2M | 106 mo ago | 4 | — | — | — | — | — |
| 36 | Ranomics Database of rare genetic variants | $1M | 117 mo ago | 6 | — | WixSentryBootstrap+17 | Top 50M | 7 patents High-throughput multisite saturation mutagenesis and splice‑junction variant analysis for gene engineering | — |
| 37 | Citation Growth Online retailer of domain names with various purchasing and financing options | $1M | 79 mo ago | — | Rahim Mohamed Co-CEO | — | — | — | — |
| 38 | Fusion Genomics Provider of molecular diagnostics and cloud-based analytic tools | $1M | 77 mo ago | 12 | Greg Stazyk Co Founder | WordPressMySQLPHP+20 | Top 10M | — | — |
| 39 | Augurex Developer of diagnostic tests to detect autoimmune and chronic diseases | $978K | 184 mo ago | 20 | — | WordPressMySQLPHP+26 | Top 50M | — | 1 award |
| 40 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 15 mo ago | — | Dominique Cheneval President and Co-Founder | — | — | 21 patents Novel benzopyran therapeutics and mRNA‑stability screening assays for drug discovery | — |
| 41 | Breathe BioMedical Developer of biomarker-based screening test for the detection of multiple diseases | $591K | 17 mo ago | 33 | Steve Graham CEO | — | — | 19 patents Patents concentrated in computing, sensing & instrumentation | 1 partnership |
| 42 | Mutagentech Provider of genome-wide sequencing solutions to detect point mutations | $552K | 12 mo ago | — | Jan Vijg Co-Founder | — | — | — | — |
| 43 | Creatus Biosciences Developer of biochemicals using synthetic biology | $320K | 57 mo ago | 6 | — | — | — | 34 patents Engineered Metschnikowia yeast for enhanced xylose transport and xylitol bioproduction | — |
| 44 | Microbiome Insights Provider of microbiome analysis solutions for academic and industrial researchers | $303K | 87 mo ago | 13 | Malcolm Kendall Co-founder & CEO | WordPressMySQLPHP+39 | Top 50M | — | — |
| 45 | Allumiqs Provider of sample preparation tools and software for omics analytics | $290K | 82 mo ago | 12 | Peter Hickey Co-Founder | WordPress Block EditorCart FunctionalityWooCommerce+31 | Top 10M | — | 1 partnership |
| 46 | Spindle Biotech Providers of tools for gene editing research | $250K | 84 mo ago | 2 | Aaron Chung CEO | — | — | 6 patents In vitro RNA synthesis reagents and methods for producing synthetic RNA molecules | — |
| 47 | Advanced Chemistry Development Labs Cheminformatics system | $245K | 61 mo ago | 183 | — | Cart FunctionalityWooCommerceWordPress+34 | Top 1M | — | 1 launch |
| 48 | Asia Green Biotechnology International biotechnology company focused on the development and evaluation of various bio-technologies | $200K | 58 mo ago | — | David Pinkman CEO | — | — | — | — |
| 49 | Entos Pharmaceuticals Provider of nanotech-based drug delivery solutions | $100K | 12 mo ago | 41 | — | GoDaddy Website BuilderGoogle MapsReact+11 | Top 10M | 53 patents Oncolytic viral therapies and SARS‑CoV‑2 nucleic‑acid vaccine platforms | 1 partnership |
Top 12 Genomics companies in Canada
#1
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
#2
Series B · Quebec City, Quebec · founded 2007 · 36 employees$40.4Mraised▾
Feldan is developing regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The company has developed Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments. The Shuttle can overcome obstacles faced by nucleic acid delivery for therapeutic use by decreasing the regulatory process and accelerating the translation of discoveries into clinical applications. The Shuttle also allows enables the development of in-house medical applications as well as in collaboration with partners.
- Apr 2025Series B—
- Feb 2025Series B—
- Sep 2024Series B$21M
- Jun 2023Series B$16.5M
#3
Public · Saint laurent, Quebec · founded 1999 · 57 employees$54Mraised▾
EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.
- Oct 2024Post IPO$43.4M
- Feb 2024Post IPO—
- Dec 2023Convertible Debt$22.5M
- Oct 2020Grant (prize money)—
#4
Series A · Vancouver, British Columbia · founded 2014 · 28 employees$5Mraised▾
Developer of personalized multi-omic digital health platform. and recommendations for health interventions by interpreting a person's genetic, metabolite, protein, and microbial molecular profiles. The company's platform is called MYHealthIntelligence, and it generates predictive and prescriptive health insights and personalized action plans covering various organs/health systems and diseases. The platform allows users to securely store, share, navigate and analyze their data on its cloud platform, and allows medical practitioners to create proactive and targeted plans.
- Aug 2025Series A$5M
#5
Public · Richmond, British Columbia · founded 2007 · 6 employees$5.3Mraised▾
Provider of metabolomics-based diagnostics for cancer. Its proprietary technology involves measurement of levels of aceylated levels of the drug Amantadine, administered to patients prior to testing. Acetylation occurs due to the presence of Spermidine N-Acetyl Transferase (SSAT),which is elevated in many cancers including lung, breast, melanoma, GI and others.
- Mar 2025Post IPO$2.5M
- Apr 2024Grant (prize money)$290K
- May 2022Post IPO$1.2M
- Jun 2021Grant (prize money)$683.4K
#6
Seed · Montreal, Quebec · founded 2025$5Mraised▾
Provider of AI-powered diagnostics platform for molecular cancer testing solutions. The platform delivers actionable insights, real-time genomic data access, and clinical insights to assist treatment decision-making. It offers ready-to-use NGS-based tissue and liquid biopsy panels that integrate into existing workflows. The platform also identifies personalized treatment options and connects to localized clinical trials.
- Feb 2025Seed$5M
#7
Public · Surrey, British Columbia · founded 1994 · 176 employees$81.4Mraised▾
Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.
- Jul 2022Post IPO$23.7M
- Oct 2020Post IPO$25.9M
- Jun 2018Post IPO$14.8M
- Jan 2018Grant (prize money)$557.5K
#8
Funding Raised · Canada · founded 2022$551.5Kraised▾
Provider of genome-wide sequencing solutions to detect point mutations. It uses range of molecular biology experiments to conduct accurate DNA sequencing on various platforms. The company has developed an error-corrected next generation sequencing platform for detecting rare somatic mutational events.
- May 2025Grant (prize money)$275.8K
- Feb 2024Grant (prize money)$275.8K
#9
Public · Richmond Hill, Ontario · founded 1997 · 40 employees$58.8Mraised▾
StaDeveloper of liquid biopsy test for the detection of cancer and multiple diseases. The company has developed blood-based biomarker tests for the early identification of colorectal cancer known as ColonSentry which uses proprietary Sentinel principle technology. Also, it develops Aristotle mRNA-based, multi-cancer panel for screening multiple cancers.
- Aug 2022Post IPO$177K
- Mar 2022Post IPO$1.5M
- Nov 2021Post IPO$3.3M
- Dec 2020Post IPO$198.3K
#10
Series A · Toronto, Ontario · founded 2018 · 34 employees$39Mraised▾
iVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines.
- Jan 2023Series A$23.8M
- Dec 2020Series A$13M
- Aug 2020Seed$250K
- Sep 2019Seed$2M
#11
Acquired · Montreal, Montreal · founded 2016 · 180 employees$165.5Mraised▾
Developer of targeted therapies to address the genetic alterations associated with selected tumors. The company uses genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead candidate, PolQ, works by inhibition of Polθ thus representing a new therapeutic opportunity, particularly in tumors that carry mutations in homology-directed repair genes.
- May 2020Series B$15M
- Sep 2019Series B$82.5M
- Jun 2017Series A$68M
#12
Public · Vancouver, British Columbia · founded 1996$37.6Mraised▾
Developer of vertical farming technology and supplier of turnkey facilities. The company provides greenhouses, growing towers, automation, and cultivation processes. It has patents for its growing towers. The company also has patent pending automated lettuce line production technology ready for commercial pilot.
- Oct 2022Post IPO$124K
- Jun 2022Post IPO—
- Jan 2022Post IPO$365.1K
- Mar 2021Post IPO$789.6K
Funding & investor landscape
Notable founders
How research on Bioinformatics is moving in Canada
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,804 Canada-affiliated papers.
- Ministry of Education187
- University of Toronto155
- University of British Columbia117
- McGill University108
- Ministry of Agriculture72
- Gene8→75
- Genome16→64
- Transcriptome2→41
- Immune system1→24
- Drug discovery2→21
- Microbiome1→19
- Gut flora1→18
- Metabolomics2→17
- Genome4→18
- Drug discovery1→10
- Disease2→55
- Clinical trial1→24
- Immune system1→19
- Gene1→19
- Epigenetics1→13
Where bioinformatics is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.